According to new statistics from the Association of the British Pharmaceutical Industry, show that the pharmaceutical industry has contributed over £1 billion to the Department of Health towards the cost of new medicines as part of the voluntary Pharmaceutical Payment Regulation Scheme (PPRS).
This will be helpful for production of new medicines as the latest treatments inexpensive for NHS patients and give UK patients the same approach to new medicines as other EU countries.
The pharmaceutical industry is now willing to advance the stream of new medicines into the NHS. The new statistics also demonstrate that the total spending of NHS on branded medicines that is from £2,136million in 2014/15 to £2,146 million in 2015/16.
According to Executive Director Commercial at ABPI, Richard Torbett, “Since 2014 our members have paid over £1billion towards a plan that they hoped would develop the stream of new medicines into the NHS patients, allowing patients to get access to treatments that are broadly available in other European countries.”
This recent PPRS plan runs for five years and offers a significant prospect to make sure that more NHS patients can take advantage from NICE standard medicines.
Dated: 9th March 2016
http://www.abpi.org.uk/media-centre/newsreleases/2016/Pages/090316.aspx